Released on: August 1, 2008, 8:20 am

Press Release Author: Dr. Sujay Singh\'s

Industry: Healthcare

Press Release Summary: IMGENEX Corporation, a San Diego based company, has obtained
exclusive world-wide rights to US Patent no. 5,830,451 from Brigham & Women\'s
Hospital, Boston, to develop and market the EBI3-p35 fusion protein also known as
Interleukin 35 (IL-35), for research purposes.

Press Release Body: IMGENEX Corporation, a San Diego based company, has obtained
exclusive world-wide rights to US Patent no. 5,830,451 from Brigham & Women\'s
Hospital, Boston, to develop and market the EBI3-p35 fusion protein also known as
Interleukin 35 (IL-35), for research purposes. IL-35 is a novel IL-12 family
cytokine produced by regulatory T cells (Treg) shown to suppress immune response
through expansion of Treg cells.

Dr. Sujay Singh, President & CEO of
IMGENEX, said that the license will allow IMGENEX to expand their presence in
the regulatory T cell reagent market and facilitate new product development. \"href=\"http://www.imgenex.com/interleukin.php
\">
IL-35 has been strongly implicated as a key player in regulating inflammatory
processes. Securing this license will allow IMGENEX to expand its presence in a key
market and sustain its role as an innovator in the life science industry.\"

For more information visit: http://www.imgenex.com
Address:-
Imgen Corporation
11175 Flintkote Avenue
SAN DIEGO, CA 92121-1318 , US
(858) 642-0978
Fax: 999 999 9999


Web Site: http://www.imgenex.com

Contact Details: Imgen Corporation
11175 Flintkote Avenue
SAN DIEGO, CA 92121-1318 , US
(858) 642-0978
Fax: 999 999 9999